[{"orgOrder":0,"company":"Genpharm","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Genpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genpharm \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Genpharm \/ Genpharm"},{"orgOrder":0,"company":"Genpharm","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Genpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genpharm \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Genpharm \/ Genpharm"},{"orgOrder":0,"company":"Genpharm","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Genpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genpharm \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Genpharm \/ Genpharm"},{"orgOrder":0,"company":"Genpharm","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Disintegrating","sponsorNew":"Genpharm \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Genpharm \/ Genpharm"},{"orgOrder":0,"company":"Genpharm","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.A.E","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Genpharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Genpharm \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Genpharm \/ Quoin Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Genpharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : Under the agreement, Genpharm will distribute Imcivree (setmelanotide) to patients in GCC countries for the treatment of hyperphagia and obesity due to Bardet-Biedl syndrome or genetically-confirmed biallelic pro-opiomelanocortin, PCSK1, or leptin recept...

                          Product Name : Imcivree

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          May 22, 2023

                          Lead Product(s) : Setmelanotide Acetate

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved FDF

                          Recipient : Rhythm Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : Under the terms of the agreement, Genpharm Services has exclusive rights to commercialize QRX003 in the Middle East and North Africa region, upon the receipt of regulatory approvals in both territories.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 11, 2021

                          Lead Product(s) : QRX003

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Quoin Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : The agreement with Genpharm advances Albireo’s global strategy for the commercialization of Bylvay in a key region following European and U.S. regulatory approvals of the use of Bylvay in patients with PFIC based on the PEDFIC study.

                          Product Name : Bylvay

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 18, 2021

                          Lead Product(s) : Odevixibat

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Approved FDF

                          Recipient : Albireo Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : Under terms of the agreements, GenPharm and GEN will be responsible for all activities related to identifying patients, driving disease awareness, and ensuring market access for Libmeldy in their respective territories.

                          Product Name : Libmeldy

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 19, 2021

                          Lead Product(s) : Atidarsagene Autotemcel

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Recipient : Orchard Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : Biohaven and Genpharm's agreement will bring NURTEC™ ODT, the first oral, quick-dissolve, calcitonin gene related peptide antagonist to patients in the Middle East and the Gulf Region.

                          Product Name : Nurtec ODT

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 27, 2020

                          Lead Product(s) : Rimegepant Sulfate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Biohaven Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank